The following article is about the guidelines for the clinical practice of cannabis medicines (CBMs) for chronic pain, developed by the International Association for the Study of Pain (IASP). The guidelines are based on a systematic review of the evidence and a consensus process involving experts and stakeholders. The article summarizes the main recommendations and rationales of the guidelines, which cover the following topics: patient selection, assessment, and education; CBM formulation, dosing, and administration; monitoring and follow-up; adverse effects and safety; and special populations and situations.

https://www.painmedicinenews.com/Clinical-Pain-Medicine/Article/04-23/Guidelines-Clinical-Practice-Cannabis-Medicines-CBMs-Chronic-Pain/70233?ses=ogst